In order to implement the principles of the Opinions on Deepening Reform of Review and Approval System and Encouraging Innovation of Drugs and Medical Devices (T.Zi (2017) No. 42) issued by General Office of the CPC Central Committee and General Office of the State Council and the Decision of the State Council on Canceling a Batch of Administrative Licensing Items (No. [2017] 46), the former CFDA issued the Announcement on Adjusting the Review and Approval of Active Pharmaceutical Ingredients, Pharmaceutical Excipients and Pharmaceutical Packaging Materials (No. 146, 2017, hereinafter referred to as Announcement No. 146) on November 30, 2017.